scholarly journals Meta-Analysis of Visual Evoked Potential and Parkinson’s Disease

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Song-bin He ◽  
Chun-yan Liu ◽  
Lin-di Chen ◽  
Zhi-nan Ye ◽  
Ya-ping Zhang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Visual Evoked Potential ◽  
Evoked Potential ◽  
Meta Analysis ◽  
Case Control ◽  
Healthy Controls ◽  
Case Control Studies ◽  
P100 Latency ◽  
Visual Evoked

Background. Previous studies suggested that visual evoked potential (VEP) was impaired in patients with Parkinson’s disease (PD), but the results were inconsistent. Methods. We conducted a systematic review and meta-analysis to explore whether the VEP was significantly different between PD patients and healthy controls. Case-control studies of PD were selected through an electronic search of the databases PubMed, Embase, and the Cochrane Central Register of Controlled Trials. We calculated the pooled weighted mean differences (WMDs) and 95% confidence intervals (CIs) between individuals with PD and controls using the random-effects model. Results. Twenty case-control studies which met our inclusion criteria were included in the final meta-analysis. We found that the P100 latency in PD was significantly higher compared with healthy controls (pooled WMD = 6.04, 95% CI: 2.73 to 9.35, P=0.0003, n=20). However, the difference in the mean amplitude of P100 was not significant between the two groups (pooled WMD = 0.64, 95% CI: −0.06 to 1.33, P=0.07) based on 10 studies with the P100 amplitude values available. Conclusions. The higher P100 latency of VEP was observed in PD patients, relative to healthy controls. Our findings suggest that electrophysiological changes and functional defect in the visual pathway of PD patients are important to our understanding of the pathophysiology of visual involvement in PD.

Effect of L-dopa on visual evoked potential in patients with Parkinson's disease

Neurology ◽  
1986 ◽  
Vol 36 (8) ◽  
pp. 1119-1119 ◽  
Author(s):  
P. A. Bhaskar ◽  
S. Vanchilingam ◽  
E. A. Bhaskar ◽  
A. Devaprabhu ◽  
R. A. Ganesan
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Visual Evoked Potential ◽  
Evoked Potential ◽  
Visual Evoked

scholarly journals Event-Related Potential and Visual Evoked Potential in Patients with Parkinson's Disease.

1993 ◽  
Vol 30 (5) ◽  
pp. 363-368 ◽  
Author(s):  
Masanaka Takeda ◽  
Hisahiro Tachibana ◽  
Bungo Okuda ◽  
Keita Kawabata ◽  
Minoru Sugita
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Visual Evoked Potential ◽  
Evoked Potential ◽  
Event Related Potential ◽  
Visual Evoked

Mutations in GBA and risk of Parkinson’s disease: a meta-analysis based on 25 case-control studies

2013 ◽  
Vol 35 (8) ◽  
pp. 873-878 ◽  
Author(s):  
Xueye Mao ◽  
Tinghua Wang ◽  
Rong Peng ◽  
Xueli Chang ◽  
Nannan Li ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Meta Analysis ◽  
Case Control ◽  
Case Control Studies

scholarly journals Impulse-Control Disorders in Parkinson’s Disease: A Meta-Analysis and Review of Case–Control Studies

2018 ◽  
Vol 9 ◽  
Author(s):  
Helge Molde ◽  
Yasaman Moussavi ◽  
Stine Therese Kopperud ◽  
Aleksander Hagen Erga ◽  
Anita Lill Hansen ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Impulse Control ◽  
Meta Analysis ◽  
Case Control ◽  
Impulse Control Disorders ◽  
Case Control Studies

The association between the LRRK2 G2385R variant and the risk of Parkinson’s disease: a meta-analysis based on 23 case–control studies

2014 ◽  
Vol 35 (10) ◽  
pp. 1495-1504 ◽  
Author(s):  
Cheng-long Xie ◽  
Jia-Lin Pan ◽  
Wen-Wen Wang ◽  
Yu Zhang ◽  
Su-fang Zhang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Meta Analysis ◽  
Case Control ◽  
Case Control Studies

scholarly journals The Association Between the Gut Microbiota and Parkinson's Disease, a Meta-Analysis

2021 ◽  
Vol 13 ◽  
Author(s):  
Ting Shen ◽  
Yumei Yue ◽  
Tingting He ◽  
Cong Huang ◽  
Boyi Qu ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Gut Microbiota ◽  
Meta Analysis ◽  
Gastrointestinal Symptoms ◽  
Short Chain Fatty Acids ◽  
Case Control ◽  
Case Control Studies ◽  
Geographical Regions ◽  
Gut Microbiota Dysbiosis

Patients with Parkinson's disease (PD) were often observed with gastrointestinal symptoms, which preceded the onset of motor symptoms. Neuropathology of PD has also been found in the enteric nervous system (ENS). Many studies have reported significant PD-related alterations of gut microbiota. This meta-analysis was performed to evaluate the differences of gut microbiota between patients with PD and healthy controls (HCs) across different geographical regions. We conducted a systematic online search for case-control studies detecting gut microbiota in patients with PD and HCs. Mean difference (MD) and 95% confidence interval (CI) were calculated to access alterations in the abundance of certain microbiota families in PD. Fifteen case-control studies were included in this meta-analysis study. Our results showed significant lower abundance levels of Prevotellaceae (MD = −0.37, 95% CI = −0.62 to −0.11), Faecalibacterium (MD = −0.41, 95% CI: −0.57 to −0.24), and Lachnospiraceae (MD = −0.34, 95% CI = −0.59 to −0.09) in patients with PD compared to HCs. Significant higher abundance level of Bifidobacteriaceae (MD = 0.38, 95%; CI = 0.12 to 0.63), Ruminococcaceae (MD = 0.58, 95% CI = 0.07 to 1.10), Verrucomicrobiaceae (MD = 0.45, 95% CI = 0.21 to 0.69), and Christensenellaceae (MD = 0.20, 95% CI = 0.07 to 0.34) was also found in patients with PD. Thus, shared alterations of certain gut microbiota were detected in patients with PD across different geographical regions. These PD-related gut microbiota dysbiosis might lead to the impairment of short-chain fatty acids (SCFAs) producing process, lipid metabolism, immunoregulatory function, and intestinal permeability, which contribute to the pathogenesis of PD.

scholarly journals Patients with Parkinson’s disease predict a lower incidence of colorectal cancer

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Hongsheng Fang ◽  
Yunlan Du ◽  
Shuting Pan ◽  
Ming Zhong ◽  
Jiayin Tang
Keyword(s):  
Colorectal Cancer ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cohort Studies ◽  
Fixed Effects ◽  
Meta Analysis ◽  
Case Control ◽  
Recent Theory ◽  
Analysis Model ◽  
Case Control Studies

Abstract Background Recent theory on the “gut-brain axis” suggests a close relationship between the dysfunction of the gut and the disorders of the brain. Methods We performed a systemic literature search followed by a multi-step inclusion selection for all studies on the risk of Colorectal cancer (CRC) in Parkinson’s disease (PD) patients using the following databases: PubMed, EMBASE and WOS. Relative risk (RR) and the 95% confidence intervals (CI) were calculated using either the random-effects model or the fixed-effects meta-analysis model, based on the assessment of heterogeneity. Results Seventeen studies involving a total of 375,964 PD patients and 879,307 cancer patients were included. Independent meta-analyses for cohort studies and case-control studies showed that the overall pooled RR of the cohort studies was 0.78 (0.66–0.91), and that of the case-control studies was 0.78 (0.65–0.94), indicating that patients with PD have a significantly decreased risk for CRC. The significant lower risk is present in both the colon and the rectum subgroups classified by tumor location. Moreover, the risk for CRC is significantly lower in America (RR = 0.58), Europe (RR = 0.82) and Asia (RR = 0.83) compared to the control population. Conclusion The occurrence of CRC was significantly lower in patients with diagnosis of PD.

Sign in / Sign up

Export Citation Format

Share Document